Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphomawmm2023-01-10T16:48:18-08:00April 28th, 2021|Read more
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation SequencingInvivoscribe Marketing2021-04-27T17:17:21-07:00April 20th, 2021|Read more
Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancersInvivoscribe Marketing2021-02-11T19:51:54-08:00November 25th, 2020|Read more
Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten statusInvivoscribe Marketing2021-02-11T19:57:34-08:00November 22nd, 2020|Read more
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality TestingInvivoscribe Marketing2021-02-17T18:10:07-08:00November 17th, 2020|Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic MalignanciesInvivoscribe Marketing2021-02-26T19:10:45-08:00May 21st, 2019|Read more
Invivoscribe To Present At Biotech Showcase™ 2019 In San Franciscowmm2021-02-26T19:10:54-08:00January 3rd, 2019|Read more
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in JapanInvivoscribe Marketing2021-02-26T19:11:02-08:00November 29th, 2018|Read more
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for QuizartinibInvivoscribe Marketing2022-09-23T16:52:06-07:00November 27th, 2018|Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in JapanInvivoscribe Marketing2021-02-26T19:11:48-08:00November 19th, 2018|Read more